RRR-α-vitamin e succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 190-200

  Yin, Yi ^a,b   Ni, Jing ^a   Chen, Ming ^a   Guo, Yinglu ^b   Yeh, Shuyuan ^a,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b PEKING UNIVERSITY   (China)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; CALCITRIOL; CALCIUM; COLECALCIFEROL RECEPTOR; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERCALCEMIA; IN VIVO STUDY; ISOMERISM; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CALCITRIOL; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; TOCOPHEROLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58849087664     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0910     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008:58:71 -96.
2. Kline K, Yu W, Sanders BG. Vitamin E and breast cancer. J Nutr 2004;134:3458-62S.
3. Neuzil J, Tomasetti M, Mellick AS, et al. Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects. Curr Cancer DrugTargets 2004;4:355-72.
4. Prasad KN, Kumar B,Yan XD, Hanson AJ, Cole WC. α-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr 2003;22:108-17.
5. WeberT, Lu M, Andera L, et al. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin Cancer Res 2002;8:863-9.
6. Yin Y, Ni J, Chen M, DiMaggio MA, GuoY, Yeh S.The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of insulinlike growth factor binding protein-3. Clin Cancer Res 2007;13:2271 -80.
7. Zhang Y, Ni J, Messing EM, Chang E, Yang CR,Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A 2002;99:7408-13.
8. Ni J, Chen M, Zhang Y, Li R, Huang J, Yeh S. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003;300:357-63.
9. Zhang M, Altuwaijri S.Yeh S. RRR-α-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 2004;23:3080-8.
10. Zhong C, Yang S, Huang J, Cohen MB, Roy-Burman P. Aberration in the expression of the retinoid receptor, RXRα, in prostate cancer. Cancer Biol Ther 2003;2: 179-84.
11. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005;26:662-87.
12. Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004;566:169-72.
13. Klein EA. Chemoprevention of prostate cancer. Crit Rev Oncol Hematol 2005;54:1-10.
14. Stewart LV, Weigel NL. Vitamin D and prostate cancer, Exp Biol Med (Maywood) 2004;229: 277-84.
15. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1, 25- dihydroxyvitamin D3 (calcitriol). J Urol 1998;159: 2035-9; discussion 9-40.
16. Gullifor dT, English J, Colston KW, Menday P, Moller S, Coombes RC. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998;78:6-13.
17. EvansTR, Colston KW, Lofts FJ, et al. A phase II trial of the vitamin D analogue seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86:680-5.
18. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1- α,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 2001;7:4164-73.
19. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005;65: 7917-25.
20. Vegesna V, O'Kelly J, Said J, Uskokovic M, Binderup L, Koeffle HP. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res 2003;23:283-9.
21. Ho SM. Estrogens and anti-estrogens, key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004;91:491 -503.
22. Peehl DM, Feldman D. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol 2004; 92:307-15.
23. Chou TC, Talalay P. Quantitative analysis of dose- effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
24. Chou TC, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621 -81.
25. Keshelava N, Davicioni E, Wan Z, et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007;99:1107-19.
26. Lou YR, Nazarova N,Talonpoika R,Tuohimaa P. 5α- dihydrotestosterone inhibits 1α,25-dihydroxyvitamin D (3)-induced expression of CYP24 in human prostate cancer cells. Prostate 2005;63:222-30.
27. Morgan J W, Kouttab N, Ford D, Maizel AL. Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations. Endocrinology 2000; 141:3225-34.
28. Rao A, Coan A.Welsh JE, Barclay WW, Koumenis C, Cramer SD. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 2004;64: 2143-7.
29. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 α25-dihy- droxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319-24.
30. Peng L, Malloy PJ, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004;18:1109-19.
31. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142-53.
32. Tallarida RJ. The interaction index: a measure of drug synergism. Pain 2002;98:163-8.
33. Trump DL, Hershberger PA, Bernardi RJ, et al. Antitumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004;89-90: 519-26.
34. Danilenko M, Studzinski GP. Enhancement by other compounds of the anti-cancer activity of vitamin D (3) and its analogs. Exp Cell Res 2004;298:339 - 58.
35. Sokoloski JA, Hodmck WF, Mayne ST, Cinquina C, Kim CS, Sartorelli AC. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-κB. Leukemia 1997;11:1546-53.
36. Danilenko M, Wang Q, Wang X, Levy J, Sharoni Y, Studzinski GP. Camosic acid potentiates the antioxidant and prodifferentiation effects of 1 α,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 2003;63:1325-32.
37. Hassoun EA, Vodhanel J, Abushaban A. The modulatory effects of ellagic acid and vitamin E succinate on TCDD-induced oxidative stress in different brain regions of rats after subchronic exposure. J Biochem Mol Toxicol 2004;18:196-203.
38. Rezk BM, Haenen GR, Van Der Vijgh WJ, Bast A. The extraordinary antioxidant activity of vitamin E phosphate. Biochim Biophys Acta 2004;1683: 16-21.
39. HedlundTE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1α.25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996;58:277-88.
40. Hedlund TE, Moffatt KA, Miller GJ. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1α, 25-dihydroxy- vitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 1996; 137:1554-61.
41. Shao A, Wood RJ, Fleet JC. Increased vitamin D receptor level enhances 1,25-dihydroxyvitamin D3- mediated gene expression and calcium transport in Caco-2 cells. J Bone Miner Res 2001;16:615-24.
42. Kumagai T, Shih LY, Hughes SV, et al. 19-Nor- 1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia Cancer Res 2005;65:2488-97.
43. Hochscheid R, Jaques G, Wegmann B Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. J Endocrinol 2000, 166:553-63.
44. Lee HY, Chun KH, Liu B, et al. Insulin-like growth factor binding protein-3 inhibits the growth of non- small cell lung cancer. Cancer Res 2002;62:3530 - 7.
45. Chan JM, Stampfer MJ, Giovannucci E, et al Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study Science 1998; 279:563-6.
46. Rajah R, Lee KW, Cohen P, Insulin-like growth factor binding protein-3 mediates tumor necrosis factor- α-induced apoptosis: role of Bcl-2 phosphorylation Cell Growth Differ 2002:13:163-71.
47. Rajah R, Valentinis B, Cohen P, Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor- β1 on programmed cell death through a p53- and IGF- independent mechanism. J Biol Chem 1997;272:12181-8.
48. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG Insulin- like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res 1996:56:1545-50.
49. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ Growth inhibitory effects of 1α 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31 Cancer Res 2001;61:7122-9.
50. Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL, CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol 2007; 103:334-7.